Resolve Nanotherapeutics (RNTx) is developing completely novel drugs for severe infections such as pneumonia, abdominal infections and others. These types of infections kill millions of people every year and our current frontline treatments – antibiotics – are rapidly losing their effectiveness due to the rise in antibiotic resistance. RNTx is taking a host-directed approach to address this problem and using cutting-edge lipid nanoparticle (LNP) RNA technology to activate the body’s natural toxin clearance systems, ultimately overcoming the devastating clinical complications and vital organ dysfunction that accompany these types of severe infections. RNTx is the product of a collaboration between the UBC labs of Dr. Pieter Cullis (LNP expert) and Dr. James Russell (critical care physician and researcher) developing de-risked technology packages in pre-clinical models of severe infection. Studies to date have demonstrated remarkable efficacy in an in vivo model of pneumonia caused by antibiotic resistant bacteria. The key strengths of the technology are: (1) that the approach is organism and antibiotic resistance agnostic, (2) it does not create a selective pressure for new resistance development, ensuring a sustained market once approved and, (3) it uses clinically validated components (LNPs and RNA) that can readily be scaled for manufacturing and widespread distribution.